The Mayo Clinic's first batch of coronavirus tests found no sign of the virus in 90 samples, a clinic official said Friday, suggesting that the virus in Minnesota is likely not widespread at this point.
Mayo Clinic Laboratories announced this week that it has begun rolling out a new coronavirus test as concerns have been building across the country about whether there's a lack of testing capabilities.
In its first 36 hours of testing, the lab at Mayo received about 200 samples, said Matthew Binnicker, director of the clinical virology lab at Mayo Clinic in Rochester. Mayo said it can perform up to 300 tests per day and could be adding technology in the coming weeks to greatly expand the volume.
"I think we want to expand testing in terms of our ability to do testing, but we also want to focus on testing patients who have symptoms and meet the clinical criteria," Binnicker said. "We really need to focus on utilizing the testing in a thoughtful way — when a physician has ordered the test and thinks, based on the patient's clinical criteria, that the test is needed."
Of the testing results thus far, Binnicker said: "That's really good news. ... The virus is here in Minnesota, but the test results suggest it is likely not widespread at this point."
The Minnesota Department of Health started testing for the virus that causes COVID-19 on Jan. 20. As of Friday, the department was reporting that 14 patients had tested positive for the virus out of about 555 patients tested.
In mid-February, Mayo fast-tracked development of a coronavirus test as the outbreak started to overwhelm the health care system in China and spread around the globe. Other commercial labs also have been launching tests this month, with the director of the federal Centers for Disease Control and Prevention (CDC) telling lawmakers Thursday that millions of tests are coming online.
The supply is arriving after some public health experts have suggested the government should have enlisted the help of labs earlier in the outbreak. There are signs the nation needs "a better system for helping states that lack capacity be able to share their samples with those labs that have spare capacity," Dr. Scott Gottlieb, the former commissioner of the Food and Drug Administration in the Trump administration, said via Twitter on Friday.